Esperion Therapeutics Inc (ESPR)
2.46
+0.05
(+2.07%)
USD |
NASDAQ |
May 22, 10:52
Esperion Therapeutics Free Cash Flow: -27.38M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -27.38M |
| December 31, 2023 | -135.49M |
| September 30, 2023 | -140.90M |
| June 30, 2023 | -164.41M |
| March 31, 2023 | -190.19M |
| December 31, 2022 | -174.83M |
| September 30, 2022 | -190.06M |
| June 30, 2022 | -216.40M |
| March 31, 2022 | -213.73M |
| December 31, 2021 | -263.81M |
| September 30, 2021 | -287.33M |
| June 30, 2021 | -304.75M |
| March 31, 2021 | -118.08M |
| December 31, 2020 | -98.55M |
| September 30, 2020 | -67.49M |
| June 30, 2020 | -39.28M |
| March 31, 2020 | -232.33M |
| December 31, 2019 | -71.29M |
| September 30, 2019 | -49.92M |
| June 30, 2019 | -29.11M |
| March 31, 2019 | -14.07M |
| December 31, 2018 | -148.79M |
| September 30, 2018 | -154.87M |
| Date | Value |
|---|---|
| June 30, 2018 | -153.18M |
| March 31, 2018 | -140.21M |
| December 31, 2017 | -131.32M |
| September 30, 2017 | -112.85M |
| June 30, 2017 | -91.27M |
| March 31, 2017 | -72.35M |
| December 31, 2016 | -47.82M |
| September 30, 2016 | -40.10M |
| June 30, 2016 | -37.70M |
| March 31, 2016 | -39.01M |
| December 31, 2015 | -38.48M |
| September 30, 2015 | -38.03M |
| June 30, 2015 | -34.97M |
| March 31, 2015 | -32.79M |
| December 31, 2014 | -32.89M |
| September 30, 2014 | -32.21M |
| June 30, 2014 | -28.14M |
| March 31, 2014 | -24.90M |
| December 31, 2013 | -18.14M |
| September 30, 2013 | -12.97M |
| June 30, 2013 | -11.10M |
| March 31, 2013 | -10.75M |
| December 31, 2012 | -10.82M |
Free Cash Flow Range, Past 5 Years
-304.75M
Minimum
Jun 2021
-27.38M
Maximum
Mar 2024
-150.77M
Average
-152.66M
Median
Free Cash Flow Benchmarks
| United Therapeutics Corp | 752.40M |
| Dynavax Technologies Corp | 52.69M |
| Heron Therapeutics Inc | -43.40M |
| Aldeyra Therapeutics Inc | -30.86M |
| Deciphera Pharmaceuticals Inc | -152.39M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 53.83M |
| Cash from Investing (Quarterly) | -0.073M |
| Cash from Financing (Quarterly) | 90.61M |
| Free Cash Flow Per Share (Quarterly) | 0.2835 |
| Free Cash Flow to Equity (Quarterly) | 53.32M |
| Free Cash Flow Yield | -8.51% |